Multiple System Atrophy (MSA) Market size was over USD 139.4 million in 2023 and is anticipated to reach USD 247.04 million by 2036, growing at around 4.5% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of multiple system atrophy is assessed at USD 144.42 million. The growth of the market can be attributed to the growing occurrence of multiple system atrophy across the world, significant shift in people’s lifestyles globally, and rising consumption of alcohol and narcotics. As per the data provided by the Rare Diseases organization, the incidence of multiple system atrophy in the United States alone is 0.6 cases per 100,000 people every year. An estimated 1,900 new cases of the disease occur each year in the country. In addition to these, increasing research and development activities to develop an effective treatment for systemic atrophies and rise in healthcare expenditure in developed and developing nations are also expected to drive growth for the market in the upcoming years. Furthermore, high exposure of people to environmental toxins is projected to offer ample growth opportunities to the market in the near future.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
4.5% |
|
Base Year Market Size (2023) |
USD 139.4 million |
|
Forecast Year Market Size (2036) |
USD 247.04 million |
|
Regional Scope |
|
The market is segmented by diagnosis into magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), tilt table test, and others, out of which, the magnetic resonance imaging (MRI) segment is anticipated to hold the largest share in the global multiple system atrophy (MSA) market on account of the high usage of MRI techniques for differentiation of systemic atrophy with Parkinson’s disease, and its usefulness in tracking the progression of multiple system atrophy. Along with this, the segment for tilt table test is also predicted to occupy a significant market share during the forecast period owing to the rising use of this test to document the extent of blood pressure irregularities, which is fundamental for diagnosing systemic atrophies.
Our in-depth analysis of the global multiple system atrophy (MSA) market includes the following segments:
|
By Type |
|
|
By Diagnosis |
|
On the basis of geographical analysis, the global multiple system atrophy (MSA) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. Asia Pacific is set to account for largest revenue share by 2036, on the back of increasing number of cases of multiple system atrophy, especially in Japan, high patient pool and growing government initiatives to improve the infrastructure of healthcare in the region. Moreover, the market in North America is expected to gather the largest share during the forecast period, which can be credited to the rising prevalence of neurological disorders, increasing healthcare spending, well established healthcare infrastructure, and strong presence of prominent market players in the region. According to the Centers for Medicare and Medicaid Services, U.S. health care spending grew 4.6 percent in 2019, reaching $3.8 trillion or $11,582 per person. The health spending accounted for 17.7 percent of the country’s total GDP share.
March 18, 2020- Biohaven Pharmaceutical’s myeloperoxidase (MPO) inhibitor, verdiperstat, received fast track designation from the United States Food and Drug Administration for treating multiple system atrophy or MSA. The drug is aimed at slowing the progression of the disease.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?